Searching for Prognostic Markers in Patients with Osteosarcoma

Tuesday, November 05, 2019

In an interview with OncLive®, a sister publication to Oncology Nursing News®, Elham Nasri, MD, resident, and pathologist at the University of Florida’s College of Medicine, discussed the procedures oncology professionals should take before determining whether patients with osteosarcoma should begin chemotherapy.

What they do is, they usually biopsy a patient's tumor and the tumor comes to us as a pathologist. We diagnose it to see if it is osteosarcoma or not, if the physicians and especially the oncologists are aware that they can use a specific markers at a time of diagnosis to help them to gauge the treatment of the patients because they will have started the chemo already, it will be helpful.

So, they can ask us to do it, because it's not a routine or a standard thing to do nowadays, and it's still a method under investigation, but what we do is that they perform immunohistochemistry on the piece of tissue that they gave us. Based on our evaluation of the percentage of the cells in that slide of tissue that express that marker, we can give them if this tumor is a high expression for P16 or P21 or not.

Talk about this article with nurses and others in the oncology community in the General Discussions Oncology Nursing News discussion group.
External Resources

MJH Associates
American Journal of Managed Care
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
OncNurse Resources

Continuing Education
Web Exclusives

About Us
Advisory Board
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2019
Intellisphere, LLC. All Rights Reserved.